FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed invention relates to field of organic chemistry, namely to hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalinyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine. Invention also relates to method of obtaining said hydrochloride salt, pharmaceutical composition, based on said hydrochloride salt, application of said hydrochloride salt.
EFFECT: novel hydrochloride salt of 4-[2-[[5-methyl-1-(2-naphthalinyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine useful at treatment and/or prevention of diseases, associated with sigma receptor, is obtained.
6 cl, 30 dwg, 11 tbl, 9 ex
Title | Year | Author | Number |
---|---|---|---|
4-[2-[[5-METHYL-1-(2-NAPHTHALINYL)-1H-PYRAZOL-3-YL]OXY]ETHYL]MORPHOLINE HYDROCHLORIDE POLYMORPH AND SOLVATES | 2011 |
|
RU2560150C2 |
METHOD OF PRODUCING NAPHTHALEN-2-YL-PYRAZOL-3-ONE INTERMEDIATE COMPOUNDS USED IN SYNTHESIS OF SIGMA RECEPTOR INHIBITORS | 2009 |
|
RU2509763C2 |
SIGMA-RECEPTOR INHIBITORS | 2005 |
|
RU2417987C2 |
PYRAZOLE COMPOUNDS AS SIGMA RECEPTOR INHIBITORS | 2011 |
|
RU2582338C2 |
SALTS OF 1-(4-(2-((1-(3,4-DIFLUOROPHENYL)-1N-PYRAZOL-3-YL)METHOXY)ETHYL)PIPERAZIN-1-YL)ETHANONE | 2016 |
|
RU2727974C2 |
USE OF SIGMA LIGANDS IN DIABETES TYPE-2 ASSOCIATED PAIN | 2012 |
|
RU2608943C2 |
SIGMA-RECEPTOR INHIBITORS | 2005 |
|
RU2404972C2 |
2-AMINOBENZOXAZOLE CARBOXAMIDES AS 5-HT3 MODULATORS | 2007 |
|
RU2448105C2 |
CRYSTALLINE FORMS OF FREE BASE | 2014 |
|
RU2675851C2 |
SUBSTITUTED PYRAZOLES, PHARMACEUTICAL COMPOSITION BASED ON SAID, METHOD OF PATIENT TREATMENT, INTERMEDIATE COMPOUND | 1993 |
|
RU2130453C1 |
Authors
Dates
2015-08-10—Published
2010-11-25—Filed